Classification criteria for antiphospholipid syndrome and its non-criterial manifestations: 616.72-002.77-07

Abstract

Summary. Today questions about the antiphospholipid syndrome (APS) criteria remain actual. This applies in particular about the need to include some clinical manifestations, as well as serological markers that are distinguishable from those classic ones, in APS criteria. The review presents the proposed profiles of non-criterial APS manifestations, and discusses the need to revise APS classification criteria.

References:

1. 
Reshetnyak T.M. Antiphospholipid syndrome: diagnosis and clini- cal manifestations (a lecture). Nauchno-prakticheskaya revma- tologiy 2014;52(1):56–71. (In Russ.). DOI: 10.14412/1995–4484– 2014–56–71. 

2. Nasonov E.L. Antiphospholipid syndrome. Moscow: Litterra, 2004. 434 pp. (In Russ.). 

3. Schreiber K., Sciascia S., de Groot P.G. et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. DOI: 10.1038/ nrdp.2017.103. 

4. Agmon-Levin N., Shoenfeld Y. The spectrum between antiphos- pholipid syndrome and systemic lupus erythematosus. Clin Rheu- matol. 2014;33(3):293–5. DOI: 10.1007/s10067–014–2486–5. 

5. Volkov I., Seguro L., Leon E.P. et al. Profiles of criteria and non-cri- teria antiphospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. Auto Immun High- lights. 2020;11(1):8. DOI: 10.1186/s13317–020–00131–3. 

6. Roggenbuck D., Egerer K., von Landenberg P. et al. Antiphospho- lipid antibody profiling: time for a new technical approach? Auto- immun Rev. 2012;11(11):821–6. DOI: 10.1016/j.autrev.2012.02.016. 

7. Zuily S., Clerc-Urmès I., Bauman C., et al; APS ACTION Investi- gators. Cluster analysis for the identification of clinical pheno- types among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus. 2020:961203320940776. DOI: 10.1177/0961203320940776. 

8. Yelnik C.M., Urbanski G., Drumez E. et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26(2):163–9. DOI: 10.1177/0961203316657433. 

9. Pengo V., Ruffatti A., Legnani C. et al. Incidence of a first throm- boembolic event in asymptomatic carriers of high-risk antiphos- pholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8. DOI: 10.1182/blood-2011–03–340232. 

10. Mekinian A., Alijotas-Reig J., Carrat F. et al; on the behalf of the SNFMI and the European Forum on Antiphospholipid Antibo- Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospec- tive study. Autoimmun Rev. 2017;16(7):730–4. DOI: 10.1016/j.aut- rev.2017.05.006. 

11. Abreu M.M., Danowski A., Wahl D.G. et al. The relevance of “non- criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Tech- nical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14. DOI: 10.1016/j.aut- rev.2015.01.002. 

12. Mekinian A., Bourrienne M.C., Carbillon L. et al. Non-conven- tional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnan- Semin Arthritis Rheum. 2016;46(2):232–7. DOI: 10.1016/j.sem- arthrit.2016.05.006. 

13. Sciascia S., Bertolaccini M.L. Antibodies to phosphatidylserine/ prothrombin complex and the antiphospholipid syndrome. Lupus. 2014;23(12):1309–12. DOI: 10.1177/0961203314538332. 

14. Shi H., Zheng H., Yin Y.F. et al. Antiphosphatidylserine/prothrom- bin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614– 24. DOI: 10.1515/cclm-2017–0502.
15. Sciascia S., Sanna G., Murru V. et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A sys- tematic review. Thromb Haemost. 2014;111(2):354–64. DOI: 10.1160/ TH13–06–0509.
16. Liu T., Gu J., Wan L. et al. “Non-criteria” antiphospholipid antibo- dies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020;22(1):33. DOI: 10.1186/ s13075–020–2131–4.
17. Roggenbuck D., Borghi M.O., Somma V., et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016;18(1):111. DOI: 10.1186/s13075–016–1018-x.
18. Nalli C., Somma V., Andreoli L. et al. Anti-phospholipid IgG anti- bodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights. 2018;9(1):6. DOI: 10.1007/s13317–018–0106–0.
19. Funke A., Staub H.L., Monticielo O.A. et al Non-criteria antiphos- pholipid antibodies: a narrative review. Rev Assoc Med Bras (1992). 2020;66(11):1595–601. DOI: 10.1590/1806–9282.66.11.1595.
20. Barbhaiya M., De Abreu M.M., Amigo M.C. Needs-assessment sur- vey for the update of the current antiphospholipid syndrome (APS) classification criteria. Ann Rheum Dis. 2015;74(Suppl 2):1087.3– 1087. DOI: 10.1136/annrheumdis-2015-eular.1330.
21. Barbhaiya M., Ercan D., Ahmadzadex Y., et al. OP0097 Develop- ment of new international classification criteria for antiphospho- lipid syndrome: Phase III case collection results. Ann Rheum Dis. 2020;79(Suppl 1):64.2–64. DOI: 10.1136/annrheumdis-2020-eu- lar.5294/
22. da Rosa P.G., Bettencourt P., Rodríguez-Pintó I., Cervera R., Espi- nosa G. “Non-criteria” antiphospholipid syndrome: A nomencla- ture proposal. Autoimmun Rev. 2020;19(12):102689. DOI: 10.1016/j. 2020.102689.

23. Hughes G.R., KhamashtaM.A.Seronegative antiphospho- lipid syndrome. Ann Rheum Dis. 2003;62(12):1127. DOI: 10.1136/ ard.2003.006163.


24. Rodriguez-Garcia J.L., Bertolaccini M.L., Cuadrado M.J. et al. Clini- cal manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis. 2012;71(2):242–4. DOI: 10.1136/annrheum- dis-2011–200614.
25. Pignatelli P., Ettorre E., Menichelli D. et al. Seronegative antiphos- pholipid syndrome: refining the value of “non-criteria” anti- bodies for diagnosis and clinical management. Haematologica. 2020;105(3):562–72. DOI: 10.3324/haematol.2019.221945.
26. Kalashnikova L., Stoynovich L., Kovalyv V. et al. Sneddon`s syn- drome and the primary antiphospholipid syndrome. Cerebrovas- cular Dis. 1994;4:76–82.
27. Asherson R.A., Piette J.C., Cervera R. “Primary”, “secondary”, “seronegative”, “catastrophic” and other subset of the antipho- spolipid syndrome. In: The Antiphospholipid Syndrome II: Autoimmune thrombosis. Eds. R.A. Asherson, J.C. Piette, R. Cer- vera, Y. Shoenfeld. Elsivier: Science, 2002. 285–96. DOI: 10.1016/ B978–044450987–1/50029–2.
28. Samanta D., Cobb S., Arya K. Sneddon syndrome: A comprehen- 
sive overview. J Stroke Cerebrovasc Dis. 2019;28(8):2098–108. DOI: 
1016/j.jstrokecerebrovasdis.2019.05.013. 

29. Conti F., Capozzi A., Truglia S. et al. The mosaic of “seronegative” 
antiphospholipid syndrome. J Immunol Res. 2014;2014:389601. 
DOI: 10.1155/2014/389601. 

30. Nasonov E.L., Reshetnyak T.M., Patrushev L.I. et al. Mutations Leiden, G20210A in the prothrombin gene and antiphospholipid antibodies in systemic lupus erythematosus and antiphospho- lipid syndrome. Terapevticheskij arhiv. 2000;(5):34–8. (In Russ.). 

31. Berman H., Ugarte-Gil M.F., Espinosa G. et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol. 2013;31(6): 926–32. 

32. Diz-Kucukkaya R., HancerV.S., Artim-Esen B. et al. The preva- lence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 2010;29(3):303–9. DOI: 10.1007/s11239–009–0356–9. 

33. Cervera R., Conti F., Doria A. et al. Does seronegative antiphos- pholipid syndrome really exist? Autoimmun Rev. 2012;11(8):581– 4. DOI: 10.1016/j.autrev.2011.10.017. 

34. Pons-Estel G.J., Andreoli L., Scanzi F. et al. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Auto- immun. 2017;76:10–20. DOI: 10.1016/j.jaut.2016.10.004. 

35. Marx-Deseure A., Labreuche J., Launay D. et al. Are pregnancies with lupus but without APS of good prognosis? Autoimmun Rev. 2020;19(4):102489. DOI: 10.1016/j.autrev.2020.102489. 

36. Pericleous C., Ferreira I., Borghi O. et al. Measuring IgA anti- β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. PLoS One. 2016;11(6): e0156407. DOI: 10.1371/jour- nal.pone.0156407. 

37. Miyakis S., Lockshin M.D., Atsumi T. et al. International con- sensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306. DOI: 10.1111/j.1538–7836.2006.01753.x. 

38. Asherson R.A. New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphos- pholipid syndromes (“MAPS”). Autoimmun Rev. 2006;6(2):76–80. DOI: 10.1016/j.autrev.2006.06.008. 

39. Alijotas-Reig J., Esteve-Valverde E., Ferrer-Oliveras R. et al; EUROAPS Study Group. Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Med Clin (Barc). 2018;151(6):215–22. [Article in English, Spanish]. DOI: 10.1016/j.medcli.2017.11.017. 

40. Alijotas-Reig J., Esteve-Valverde.E, Ferrer-Oliveras R. et al; EUROAPS Study Group. Comparative study of obstetric antiphos- pholipid syndrome (OAPS) and non-criteria obstetric APS (NC- OAPS): report of 1640 cases from the EUROAPS registry. Rheuma- tology (Oxford). 2020;59(6):1306–14. DOI: 10.1093/rheumatology/ kez419. 

41. Alijotas-Reig J., Ferrer-Oliveras R.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus. 2012;21(7):766– DOI: 10.1177/0961203312440058. 

42. Meroni P.L., Chighizola C.B., Gerosa M. et al. Obstetric antiphos- pholipid syndrome: lobsters only? Or should we also look for selected red herrings? J Rheumatol. 2015;42(2):158–60. DOI: 10.3899/jrheum.141407. 

43. Clark C.A., Spitzer K.A., Laskin C.A. Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring? J Rheu- matol. 2015;42(2):155–7. DOI: 10.3899/jrheum.140760. 

44. Simchen M.J., Dulitzki M., Rofe G. et al. High positive antibody titers and adverse pregnancy outcome in women with antiphos- pholipid syndrome. Acta Obstet Gynecol Scand. 2011;90(12):1428– 33. DOI: 10.1111/j.1600–0412.2011.01236.x.
45. Ruffatti A., Favaro M., Calligaro A. et al. Management of preg- nant women with antiphospholipid antibodies. Expert Rev Clin Immunol. 2019;15(4):347–58. DOI: 10.1080/1744666X.2019.1565995.
46. Mekinian A., Loire-Berson P., Nicaise-Roland P. et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol. 2012;94(2):222–6. DOI:10.1016/j.jri.2012.02.004.
47. Ahluwalia J., Sreedharanunni S., Kumar N. et al. Thrombotic pri- mary antiphospholipid syndrome: the profile of antibody positi- vity in patients from North India. Int J Rheum Dis. 2016;19(9):903– DOI: 10.1111/1756–185X.12479.
48. Khogeer H., Alfattani A., Al Kaff M. et al. Antiphosphatidylse- rine antibodies as diagnostic indicators of antiphospholipid syn- Lupus. 2015;24(2):186–90. DOI: 10.1177/0961203314552462.
49. Lo H.W., Chen C.J., Tsai E.M. Pregnancy outcomes for women with non-criteria antiphospholipid syndrome after anticoagu- lant therapy. Eur J Obstet Gynecol Reprod Biol. 2020;244:205–7. DOI: 10.1016/j.ejogrb.2019.11.002.
50. Ofer-Shiber S., Molad Y. Frequency of vascular and pregnancy mor- bidity in patients with low vs. moderate-to-high titers of antiphos- pholipid antibodies. Blood Coagul Fibrinolysis. 2015;26(3):261–6. DOI: 10.1097/MBC.0000000000000218.
51. Arachchillage D.R.J., Laffan M. Pathogenesis and management of antiphospholipid syndrome. Br J Haematol. 2017;178(2):181–95. DOI: 10.1111/bjh.14632.
52. Arachchillage D.R., Machin S.J., Mackie I.J., Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. Thromb Haemost. 2015;113(1):13–9. DOI: 10.1160/TH14–05–0416.
53. Abdel-Wahab N., Lopez-Olivo M.A., Pinto-Patarroyo G.P., Suarez- Almazor M.E. Systematic review of case reports of antiphospho- lipid syndrome following infection. Lupus. 2016;25(14):1520–31. DOI: 10.1177/0961203316640912.
54. Nasonov E.L. Coronavirus Disease 2019 (COVID-19): a Rheu- matologist’s thoughts. Nauchno-prakticheskaya revmatologiya. 2020;58(2):123–32. (In Russ.). DOI: 10.14412/1995–4484–2020– 123–132.
55. Nasonov E.L., Beketova T.V., Reshetnyak T.M. et al. Coronavi- rus Disease 2019 (COVID-19) and immune-mediated inflamma- tory rheumatic diseases: at the crossroads of thromboinflamma- tion and autoimmunity. Nauchno-prakticheskaya revmatologiya. 2020;58(4):353–67. (In Russ.). DOI: 10.47360/1995–4484–2020– 353–367.

1. Vassalo J., Spector N., de Meis E.et al. Antiphospholipid anti- bodies in critically ill patients with cancer: a prospective cohort J Crit Care. 2014;29(4):533–8. DOI: 10.1016/j.jcrc.2014.02.005.
2. Dlott J.S., Roubey R.A. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep. 2012;14(1):71– 8. DOI: 10.1007/s11926–011–0227–1.
3. Ruiz-Irastorza G., Hunt B.J., Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospho- lipid antibodies. Arthritis Rheum. 200715;57(8):1487–95. DOI: 10.1002/art.23109.
4. Sciascia S., Radin M., Bazzan M., Roccatello D. Novel diagnos- tic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med. 2017;12(1):1–7. DOI: 10.1007/s11739– 016–1596–2.
5. Reshetnyak T.M., Voitsekhovskaya B., Alekberova Z.S. et al. Anti- bodies to various phospholipids in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Klini- cheskaya medicina. 1999;77(5):32–7. (In Russ.).
6. Reshetnyak T.M., Zabek Yа., Alekberova Z.S. et al. Antiphospho- lipide antibodies subtypes in systemic lupus erythematosus and antiphospholipid syndrome. Nauchno-prakticheskaya revma- tologiya. 2005; 43 (5): 11–8. (In Russ.). DOI: 10.14412/1995–4484– 2005–34.